We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 18.00 | 0.16% | 11,268.00 | 11,222.00 | 11,226.00 | 11,362.00 | 11,220.00 | 11,250.00 | 3,556,178 | 16:35:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.21 | 173.96B |
From Apr 2019 to Apr 2024
By Josee Rose
AstraZeneca PLC (AZN) on Tuesday said the U.S. Food and Drug Administration has accepted a supplemental biologics license application for Imfinzi, granting the drug Priority Review status.
Imfinzi is being developed to treat patients with stage 3 unresectable non-small cell lung cancer whose disease hasn't progressed after some chemoradiation therapy.
Imfinzi has had positive data from a phase 3 trial, which continues to evaluate overall survival, one of its primary endpoints.
Write to Josee Rose at josee.rose@wsj.com.
(END) Dow Jones Newswires
October 17, 2017 02:46 ET (06:46 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
